Systematic review of allelic exchange experiments aimed at identifying mutations that confer drug resistance in Mycobacterium tuberculosis

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 2, 2014, Pages 331-342

  Nebenzahl Guimaraes, Hanna ^a,b,c,d   Jacobson, Karen R ^e,f   Farhat, Maha R ^g   Murray, Megan B ^a,g  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c UNIVERSITY OF MINHO   (Portugal)

^d UNIVERSITY OF MINHO   (Portugal)

^e BOSTON MEDICAL CENTER   (United States)

^f UNIVERSITY OF STELLENBOSCH   (South Africa)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Genetics; In vitro resistance; M. tuberculosis; Microbial susceptibility tests; SNPs

Indexed keywords

CIPROFLOXACIN; ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLONE DERIVATIVE; RIFAMPICIN; RIFAMYCIN; SPACER DNA;

ALLELE; ALLELIC EXCHANGE; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; CODON; DRUG RESISTANT TUBERCULOSIS; EMBB GENE; EMBC GENE; FRAMESHIFT MUTATION; FURA KATG GENE; GENE; GENETIC MANIPULATION; GENOTYPE; GYRA GENE; GYRB GENE; INHA GENE; KATG GENE; MISSENSE MUTATION; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NONSENSE MUTATION; PHENOTYPE; POINT MUTATION; PROMOTER REGION; REVIEW; RPOB GENE; SITE DIRECTED MUTAGENESIS; SYSTEMATIC REVIEW;

GENETICS; IN VITRO RESISTANCE; M. TUBERCULOSIS; MICROBIAL SUSCEPTIBILITY TESTS; SNPS;

ALLELES; ANIMALS; ANTITUBERCULAR AGENTS; HUMANS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84892459023     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt358     Document Type: Review

References (59)

1. WHO. Global Tuberculosis Report 2012. Geneva: WHO. http://apps.who. int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf (2 May 2013, date last accessed).
2. Menzies D, Benedetti A, Paydar A et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with monoresistance to isoniazid: a systematic review and meta-analysis. PLoS Med 2009; 6: e1000150.
3. Evans CA. GeneXpert-a game-changer for tuberculosis control? PLoS Med 2011; 8: e1001064.
4. Kim SY, Kim H, Kim SY et al. The Xpertw MTB/RIFassay evaluation in South Korea, acountry withanintermediate tuberculosis burden. Int J Tuberc Lung Dis 2012; 16: 1471-6.
5. Jacobson KR, Theron D, Kendall EA et al. Implementation of Geno Type MTBDRplus reduces time to multidrug-resistant tuberculosis therapy initiation in South Africa. Clin Infect Dis 2012; 56: 503-8.
6. Siddiqi N, Shamim M, Hussain S et al. Molecular characterization of multi-drug resistant isolates of Mycobacterium tuberculosis from patients in North India. Antimicrob Agents Chemother 2002; 46: 443-50.
7. Tang K, Sun H, Zhao Y et al. Characterization of rifampin-resistant isolates of Mycobacterium tuberculosis fromSichuanin China. Tuberculosis2013;93:89-95.
8. Tessema B, Beer J, Emmrich F et al. Analysis of gene mutations associated with isoniazid, rifampicin and ethambutol resistance among Mycobacterium tuberculosis isolates from Ethiopia. BMC Infect Dis 2012;10: 12-37.
9. Bottger EC. The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clin Microbiol Infect 2011; 17: 1128-34.
10. BoshoffHI, Mizrahi V. Purification, gene cloning, targeted knockout, overexpression, and biochemical characterization of the major pyrazinamidase from Mycobacterium smegmatis. J Bacteriol 1998; 180:5809-14.
11. Heym B, Stavropoulos E, Honore N et al. Effects of overexpression of the alkyl hydroperoxide reductase AhpC on the virulence and isoniazid resistance of Mycobacterium tuberculosis. Infect Immun 1997; 65:1395-401.
12. Bergval IL, Schuitema AR, Klatser PR et al. Resistant mutants of Mycobacterium tuberculosis selected in vitro do not reflect the in vivo mechanism of isoniazid resistance. J Antimicrob Chemother 2009; 64:515-23.
13. Aubry A, Pan X, Fisher LM et al. Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity. Antimicrob Agents Chemother 2004; 48: 1281-8.
14. Pym AS, Saint-Joanis B, Cole ST. Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. Infect Immun 2002; 70: 4955-60.
15. Pym AS, Domenech P, Honoré N et al. Regulation of catalase- peroxidase (KatG) expression, isoniazid sensitivity and virulence by furA of Mycobacterium tuberculosis. Mol Microbiol 2001; 40: 879-89.
16. Vilcheze C, Wang F, Arai M et al. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nat Med 2006; 12: 1027-9.
17. Richardon E, Lin S, Pinsky B et al. First documentation of isoniazid reversion in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009; 13:1347-54.
18. Ando H, Kitao T, Miyoshi-Akiyama T. Downregulation of katG expression is associated with isoniazid resistance in Mycobacterium tuberculosis. Mol Microbiol 2011; 79: 1615-28.
19. SafiH, Sayers B, Hazbon MH et al. Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid, and rifampin. Antimicrob Agents Chemother 2008;52: 2027-34.
20. Starks AM, Gumusboga A, Plikaytis BB et al. Mutations at embB codon 306 are an important molecular indicator of ethambutol resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2009;53:1061-6.
21. Plinke C, Walter K, Alv S et al. Mycobacterium tuberculosis embB codon 306 mutations confer moderately increased resistance to ethambutol. Antimicrob Agents Chemother 2011; 55: 2891-6.
22. Goude R, Amin A, Chatterjee D et al. The arabinosyltransferase EmbC is inhibited by ethambutol in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2009; 53: 4138-46.
23. SafiH, Fleischmann RD, Peterson SN et al. Allelic exchange and mutant selection demonstrate that common clinical embCAB gene mutations only modestly increase resistance to ethambutol in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2010; 54:103-8.
24. Williams DL, Spring L, Collins L et al. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998; 42: 1853-7.
25. Gill SK, Garcia GA. Rifamycin inhibition of WT and Rif-resistant Mycobacterium tuberculosis and Escherichia coli RNA polymerase in vitro. Tuberculosis 2011; 91: 361-9.
26. Zaczek A, Brzostek A, Augustynowicz-Kopec E et al. Genetic evaluation of relationship between mutations in rpoB and resistance of Mycobacterium tuberculosis to rifampin. BMC Microbiol 2009; 9: 10.
27. Siu GKH, Zhang Y, Lau TCK et al. Mutations outside the rifampicin resistance-determining region associated with rifampicin resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 2011; 66: 730-3.
28. Onodera Y, Tanaka M, Sato K. Inhibitory activity of quinolones against DNA gyrase of Mycobacterium tuberculosis. J Antimicrob Chemother 2001;47: 447-50.
29. Aubry A, Veziris N, Cambau E et al. Novel gyrase mutations in quinoloneresistant and-hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob Agents Chemother 2006; 50: 104-12.
30. Matrat S, Veziris N, Mayer C et al. Functional analysis of DNA gyrase mutant enzymes carrying mutations at position 88 in the A subunit found in clinical strains of Mycobacterium tuberculosis resistant to fluoroquinolones. Antimicrob Agents Chemother 2006; 50: 4170-3.
31. Malik S, Willby M, Sikes D et al. New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. PLoS One 2012; 7: e39754.
32. Kim H, Nakajima C, Kim YU et al. Influence of lineage-specific aminoacid dimorphisms in GyrA on Mycobacterium tuberculosis resistance to fluoroquinolones. Jpn J Infect Dis 2012; 65: 72-4.
33. Matrat S, Aubry A, Mayer C et al. Mutagenesis in the a3a4 GyrA helix and in the toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. Antimicrob Agents Chemother 2008; 52: 2909-14.
34. Sun Z, Zhang J, Zhang X et al. Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates. Int J Antimicrob Agents 2008; 31: 115-21.
35. Shi R, Zhang J, Li C et al. Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing high-pressure liquid chromatography and DNA sequencing. J ClinMicrobiol 2006; 44: 4566-8.
36. Kim H, Nakajima C, Yokoyama K et al. Impact of the E540V amino acid substitution in GyrB of Mycobacterium tuberculosis on quinolone resistance. Antimicrob Agents Chemother 2011; 55: 3661-7.
37. Pantel A, Petrella S, Veziris N et al. Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis. Antimicrob Agents Chemother 2012; 56: 1990-6.
38. Pantel A, Petrella S, Matrat S et al. DNA gyrase inhibition assays are necessary to demonstrate fluoroquinolone resistance secondary to gyrB mutations in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2011; 55: 4524-9.
39. Hirsch MS, Günthard HF, Schapiro JMet al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Top HIV Med 2008; 16: 266-85.
40. Schön T, Juréen P, Chryssanthou E et al. Rifampicin-resistant and rifabutin-susceptible Mycobacterium tuberculosis strains: a breakpoint artefact? J Antimicrob Chemother 2013; 68: 2074-7.
41. Jacobson KR, Tierney DB, Jeon CY et al. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010; 51: 6-14.
42. Rustomjee R, Lienhardt C, Kanyok T et al. A phase II study of the sterilizing activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008; 12: 128-38.
43. Wang JY, Wang JT, Tsai TH et al. Addingmoxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis. Int J Tuberc Lung Dis 2010; 14: 65-71.
44. TakiffH, Guerrero E. Current prospects for the fluoroquinolones as first-line tuberculosis therapy. Antimicrob Agents Chemother 2011; 55: 5421-29.
45. Maruri F, Sterling TR, Kaiga AW. Asystematic reviewof gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother 2012; 67:819-31.
46. Sandgren A, Strong M, Muthukrishnan P et al. Tuberculosis drug resistance mutation database. PLoS Med 2009; 6: e2.
47. Cavusoglu C, Turhan A, Akinci P et al. Evaluation of the Genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis isolates. J Clin Microbiol 2006; 44: 2338-42.
48. Somoskovi A, Dormandy J, Mitsani D et al. Use of smear-positive samples to assess the PCR-based genotype MTBDR assay for rapid, direct detection of the Mycobacterium tuberculosis complex as well as its resistance to isoniazid and rifampin. J Clin Microbiol 2006; 44:4459-63.
49. Aslan G, Tezcan S, Emekdas G. Evaluation of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in clinical Mycobacterium tuberculosis complex clinical isolates. Mikrobiyol Bul 2009;43: 217-26.
50. Hillemann D, Rusch-Gerdes S, Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin, capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2009; 47: 1767-72.
51. Huang WL, Chi TL, Wu MH et al. Performance assessment of the Geno Type MTBDRsl test and DNA sequencing for detection of second-line and ethambutol drug resistance among patients infected with multidrugresistant Mycobacteriumtuberculosis. J Clin Microbiol 2011; 49: 2502-8.
52. Brossier F, Veziris N, AubryAet al. Detection of GenoType MTBDRsl test of complex mechanismsof resistance to second-line drugsand ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2010; 48: 1683-9.
53. Said HM, Kock MM, Ismail NA et al. Evaluation of the GenoType MTBDRsl assay for susceptibility testing of second-line anti-tuberculosis drugs. Int J Tuberc Lung Dis 2012; 16: 104-9.
54. Srivastava S, Garg A, Ayyagari A et al. Nucleotide polymorphism associated with ethambutol resistance in clinical isolates of Mycobacterium tuberculosis. Curr Microbiol 2006; 53: 401-5.
55. Ramaswamy SV, Amin AG, Goksel S et al. Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000;44: 326-36.
56. Srivastava S, Ayyagari A, Dhole TN et al. embB nucleotide polymorphisms and the role of embB 306 mutations in Mycobacterium tuberculosis resistance to ethambutol. Int J Med Microbiol 2009; 299: 269-80.
57. VanDeun A, Barrera L, Bastian I et al. Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results. J Clin Microbiol 2009; 47: 3501-6.
58. Hazbon MH, Motiwala AS, Cavatore M et al. Convergent evolutionary analysis identifies significant mutations in drug resistance targets of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2008; 52: 3369-76.
59. Farhat MR, Shapiro BJ, Kieser KJ et al. Convergent evolution reveals targets of positive selection in drug resistant Mycobacterium tuberculosis strains. Nat Genet 2013; in press.